Pressrelease, Uppsala 30th January 2020

 

Nanexa extends cooperation with Swedish biotech company

At the end of 2018, Nanexa signed a “Material Transfer Agreement” with a Swedish biotech company to evaluate the PharmaShell® technology with their specific drug substance. The evaluation has so far produced good results and the company has now decided to continue the project with activities to optimize the formulation. In this extended collaboration, Nanexa will produce test materials that will be evaluated in an animal study conducted by the company.

Nanexa receives a smaller payment for the work performed. The animal study is funded by the biotech company.

The company’s CEO David Westberg comments

It is very gratifying that the evaluation of PharmaShell® has produced good results in the evaluation already carried out by the biotech company and that the company now chooses to proceed with an optimized formulation in another animal study. I see this as a natural step towards a more comprehensive product development agreement and clinical evaluation.

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.